The Multiple Sclerosis Market Will Grow 10 Percent Annually Through 2018 As ... The Providence Journal ... be followed by the emergence of more-convenient reformulations of platform injectables and three highly efficacious monoclonal antibodies-- Genzyme/Bayer HealthCare's Lemtrada, Roche/Genentech's ocrelizumab and Biogen Idec/AbbVie's daclizumab. |
